Format

Send to

Choose Destination
See comment in PubMed Commons below
J Neurol Sci. 2008 Nov 15;274(1-2):1-4. doi: 10.1016/j.jns.2008.06.040. Epub 2008 Sep 3.

New targets for treatment of multiple sclerosis.

Author information

  • 1Department of Neurology and Neurological Sciences, Interdepartmental Program in Immunology, Stanford University, Stanford CA 94305, United States. Steinman@stanford.edu

Abstract

By studying gene transcripts in active lesions of multiple sclerosis via robotic sequencing and gene chips, as well as studying the very same tissue via proteomics, we have discovered several targets at the tipping points in pathophysiologic pathways controlling relapse and remission in multiple sclerosis. In this Charcot Lecture, I shall focus on osteopontin-the binding partner for alpha4 beta 1 integrin, on alpha B crystallin and on two members of the coagulation cascade tissue factor and the inhibitor of protein C. These four proteins are critical in controlling relapse and remission in MS.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk